In Vitro Activities of Gatifloxacin against Bacteria isolated from Respiratory Specimens of Patients of University Hospitals in Korea
Infection and Chemotherapy
;
: 68-74, 2004.
Article
in Korean
| WPRIM
| ID: wpr-721413
ABSTRACT
BACKGROUND:
Gatifloxacin, a new 8-methoxyquinolone, has a broad-spectrum activity with expanded potency against respiratory pathogens. In this study, we examined the in vitro activity of gatifloxacin and comparators against recently isolated bacteria from respiratory specimens of patients in Korean hospitals.METHODS:
Forty-nine isolates were from respiratory specimens of patients with acute exacerbations of chronic lower respiratory infections in eight university hospitals and 108 isolates were from respiratory specimens from patients of Yonsei University Hospital. Minimum inhibitory concentrations (MICs) were determined by NCCLS agar dilution method.RESULTS:
MIC90 of gatifloxacin for Streptococcus pneumoniae was 1 g/mL, which was 8-fold and 2-fold lower than those of ciprofloxacin and levofloxacin, respectively. All strains of Haemophilus in fluenzae and Moraxella (Branhamella) catarrhalis were inhibited by < or =0.06 g/mL and < or =0.25 g/mL of gatifloxacin, respectively, and were susceptible to all fluoroquinolones tested. MIC90 of gatifloxacin for Klebsiella pneumoniae was 0.06 g/mL, which was 2-fold lower than those of levofloxacin and moxifloxacin.CONCLUSION:
Gatifloxacin is highly active against S. pneumoniae, H. influenzae and M. (B.) catarrhalis isolated from respiratory specimens of patients of university hospitals in Korea.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pneumonia
/
Respiratory Tract Infections
/
Streptococcus pneumoniae
/
Bacteria
/
Ciprofloxacin
/
Microbial Sensitivity Tests
/
Haemophilus
/
Moraxella catarrhalis
/
Fluoroquinolones
/
Agar
Limits:
Humans
Country/Region as subject:
Asia
Language:
Korean
Journal:
Infection and Chemotherapy
Year:
2004
Type:
Article
Similar
MEDLINE
...
LILACS
LIS